Ocugen Provides Business Update with First Quarter 2025 Financial Results
May 9, 2025
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer
November 29, 2021
Related Post
-
-
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 7, 2025
-
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
May 7, 2025
-
Pacaso — The $1.3 Trillion Secret That Everyday Investors Are Finally Invited To
May 6, 2025